CRVS News and Press, Corvus Pharmaceuticals Inc. From 05/02/24

2024-05-02 10:26:34 ET More on Corvus Pharmaceuticals Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earnings data for Corvus Pharmaceuticals Financial information ...

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise...

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE...

2024-03-19 21:02:11 ET Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Conference Call March 19, 2024 04:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jeff Arcara - CBO Conference Call Participants ...

2024-03-19 16:04:18 ET More on Corvus Pharmaceuticals Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earnings data for Corvus Pharmaceuticals Financial information for Corvus Pharmaceuticals Read the full article on Seeking Alpha ...

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potentia...

2024-03-17 08:20:00 ET Wall Street has reached a notable lull in the pace of quarterly releases. Still, investors are eagerly anticipating important announcements from FedEx ( NYSE: FDX ) and a set of prominent consumer brands, such as Nike ( NYSE: NKE ), Lululemon Athl...

BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update a...

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Key...

2024-02-08 17:13:43 ET Gainers: Farmer Brothers  ( FARM ) +15% . Corvus Pharmaceuticals  ( CRVS ) +10% . Impinj ( PI ) +9% . CalAmp ( CAMP ) +6% . Arbutus Biopharma Corporation ( ABUS ) +6% . Losers: Affirm Hold...